The FDA approved Milestone Pharmaceuticals’ nasally delivered emergency treatment Cardamyst (etripamil) for a form of cardiac arrhythmia, the company confirmed. Cardamyst had been turned down twice previously; the approval follows additional data and manufacturing or labeling changes that addressed agency concerns. The nasal route targets rapid onset in outpatient or emergency settings. Approval gives Milestone a commercial product in an acute cardiovascular niche and may influence investor sentiment and M&A interest in small cardiovascular specialty developers. Clinicians will watch real‑world uptake and positioning against IV or oral antiarrhythmics in emergency protocols.